KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Opko Health (OPK) Research & Development (2016 - 2026)

Opko Health filings provide 17 years of Research & Development readings, the most recent being $29.2 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 5.32% to $29.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $122.4 million, a 15.87% increase, with the full-year FY2025 number at $124.0 million, up 17.89% from a year prior.
  • Research & Development hit $29.2 million in Q1 2026 for Opko Health, down from $32.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $32.8 million in Q4 2025 to a low of $17.3 million in Q2 2022.
  • Median Research & Development over the past 5 years was $23.0 million (2024), compared with a mean of $24.5 million.
  • Biggest five-year swings in Research & Development: skyrocketed 78.05% in 2023 and later plummeted 32.72% in 2024.
  • Opko Health's Research & Development stood at $19.5 million in 2022, then decreased by 0.69% to $19.4 million in 2023, then surged by 48.34% to $28.8 million in 2024, then increased by 13.91% to $32.8 million in 2025, then fell by 10.9% to $29.2 million in 2026.
  • The last three reported values for Research & Development were $29.2 million (Q1 2026), $32.8 million (Q4 2025), and $30.1 million (Q3 2025) per Business Quant data.